MAP2K7 and melanoma: Since 2011, however, the rules of stage IV melanoma treatment have been completely rewritten, with the introduction of Targeted Therapies (TTs) with BRAF and MEK inhibitors (BRAF+MEKi) [4,5,6], and of immunotherapy with anti CTLA-4 [7] and anti-PD-1 [8,9].